search icon
  • Print
  • ShareThis
  • Text Size
  • NIH Member Spotlight: Dr. Vance Fowler

    Principal Investigator, Antimicrobial Resistance Leadership Group, Duke University, Durham, NC

    Vance Fowler

    Dr. Vance Fowler is a clinician scientist focused on clinical and translational research involving antibiotic-resistant bacteria. He is a professor in the Departments of Medicine and Molecular Genetics & Microbiology at Duke University Medical Center and for two decades he has focused on the diagnosis, treatment, and understanding of methicillin-resistant Staphylococcus aureus (MRSA).

    Dr. Fowler’s NIH supported research

    Dr. Fowler is currently the Corresponding Principal Investigator (PI) of the Antibacterial Resistance Leadership Group (ARLG), a $62 million NIH grant facilitated by the Duke Clinical Research Institute that develops, designs, implements, and manages a clinical research agenda to increase the ability to combat antibacterial resistance (AR). The ARLG, launched in 2013 with funding from the National Institute of Allergies and Infectious Diseases (NIAID), aims to advance research by building transformational trials that will change clinical practice and reduce the impact of antimicrobial resistance.

    To date, the ARLG has reviewed more than 70 study proposals and initiated more than 30 clinical studies, including:

    • clinical testing of new drugs to treat multidrug-resistant Gram-negative bacteria
    • evaluating diagnostic devices in clinical settings
    • evaluating the effectiveness of new antibacterial stewardship programs
    • optimizing treatment regimens to reduce the emergence of resistance.

    ARLG also draws on the creativity of the global research community by inviting concept submissions to identify and address AR priorities.

    Impact on Patients and Public Health

    These collaborative networks of researchers are vital to sustained efforts to combat and understand infectious diseases. Antimicrobial-resistant bacteria cause more than 2 million infections and about 23,000 deaths each year in the United States, resulting in approximately $20 billion in excess medical spending and $35 billion in total costs, including lost productivity. NIAID created the ARLG to address key clinical research questions of the antibacterial resistance problem in a well-coordinated manner, and it is essential to continued progress in the fight against antibiotic-resistant infections.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site